Incidence of Non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: An ACTG longitudinal linked randomized trials analysis

Oncology

Volumn 80, Issue 1-2, 2011, Pages 42-49

  Krishnan, Supriya ^a   Schouten, Jeffrey T ^b   Jacobson, Denise L ^a   Benson, Constance A ^c   Collier, Ann C ^b   Koletar, Susan L ^d   Santana, Jorge ^e   Sattler, Fred R ^f   Mitsuyasu, Ronald ^g  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral treatment; Cancer; CD4 T cell counts; HIV; Non AIDS defining

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANUS CANCER; ARTICLE; BASAL CELL CARCINOMA; BLADDER CANCER; BONE CANCER; BOWEN DISEASE; BREAST CANCER; CANCER OF UNKNOWN PRIMARY SITE; CD4 LYMPHOCYTE COUNT; CIGARETTE SMOKING; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LARYNX CANCER; LEUKEMIA; LIP CANCER; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MOUTH CANCER; NEOPLASM; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; RISK ASSESSMENT; STOMACH CANCER; T CELL LYMPHOMA; TESTIS CANCER; THYROID CANCER; TONSIL CANCER;

ADULT; AGE FACTORS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SMOKING; TIME FACTORS;

EID: 79956187631     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000328032     Document Type: Article

References (37)

1. Mitsuyasu R: Non-AIDS defining malignancies in HIV. Top HIV Med 2008; 16: 117-121.
2. Engels EA: Non-AIDS defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS 2009; 23: 875-885.
3. Pantanowitz L, Dezube BJ: Evolving spectrum and incidence of non-AIDS defining malignancies. Curr Opin HIV AIDS 2009; 4: 27-34.
4. Crum-Cianflone N, Huppler Hullsiek K, Marconi V, et al: Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 2009; 23: 41-50.
5. Simard EP, Engels EA: Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis 2010; 51: 957-962.
6. Bonnet F, Burty C, Lewden C, et al: Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis 2009; 48: 633-639.
7. Shiels MS, Cole SR, Kirk GD, Poole C: A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52: 611-622.
8. Powles T, Robinson D, Stebbing J, et al: Highly active antiretroviral therapy and the incidence of non-AIDS defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884-890.
9. Deeks SG, Phillips AN: HIV infection, antiretroviral treatment ageing and non-AIDS related morbidity. BMJ 2009; 338: 288-292.
10. Patel P, Hanson DL, Sullivan PS, et al: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148: 728-736. (Pubitemid 351717418)
11. Prosperi MCF, Cozzi-Lepri A, Castagna A, et al: Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 count. Evidence from a large Italian Cohort Study. Clin Infect Dis 2010; 50: 1316-1320.
12. Smurzynski M, Collier AC, Koletar S, et al: AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics. HIV Clin Trials 2008; 9: 269-282.
13. Shafer R, Smeaton L, Robbins GK, et al: Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349: 2304-2315. (Pubitemid 37509738)
14. Robbins GK, DeGruttola V, Shafer R, et al: Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349: 2293-2303. (Pubitemid 37509737)
15. Gulick RM, Ribaudo HJ, Shikuma CM, et al: Triple-nucleoside regimens vs. efavirenzcontaining regimens for the initial treatment of HIV-1 infection: AIDS Clinical Trials Group (ACTG) Study A5095. N Engl J Med 2004; 350: 1850-1861.
16. Gulick RM, Ribaudo HJ, Shikuma CM, et al: Three-vs. four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296: 769-781. (Pubitemid 44223101)
17. Landay AL, Spitzler J, Kessler H, et al: Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reversetranscriptase inhibitor-or protease inhibitor-containing antiretroviral regimen. J Infect Dis 2003; 188: 1444-1454. (Pubitemid 37523929)
18. Riddler SA, Haubrich R, DiRienzo G, et al: A prospective, randomized, phase III trial of NRTI-, PI-, or NNRTI-sparing regimens for initial treatment of HIV-1 infection (ACTG 5142). XVI International AIDS Conference, Toronto, 2006.
19. Haubrich RH, Riddler SA, DiRienzo G, et al: Drug resistance at virologic failure in a randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection (ACTG 5142). XVI International HIV Drug Resistance Workshop, Barbados, 2007.
20. Fischl MA, Ribaudo HJ, Collier AC, et al: A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis 2003; 188: 625-634. (Pubitemid 37115174)
21. Centers for Disease Control (CDC): 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescent and adults. MMWR Morb Mortal Wkly Rep 1992; 41: 961-962.
22. Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL: Relationship between CD4+ T-cell count/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study. J Acquir Immune Defic Syndr 2010; 55: 117-127.
23. Silverberg MJ, Neuhaus J, Bower M, et al: Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21: 1957-1963. (Pubitemid 47329772)
24. Burgi A, Brodine S, Wegner S, et al: Incidence and risk factors for the occurrence of non-AIDS defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104: 1505-1511. (Pubitemid 41356166)
25. Baker JV, Peng G, Rapkin J, et al: CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22: 841-848. (Pubitemid 351563833)
26. Bedimo RJ, McGinnis KA, Dunlap M, et al: Incidence of non-AIDS-defining malignancies in HIV-infected versus non-infected patients in the HAART era. J Acquir Immune Defic Syndr 2009; 52: 203-208.
27. Bruyand M, Thiébaut R, Lawson-Ayayi S, et al: Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis 2009; 49: 1109-1116.
28. Vajdic CM, van Leeuwen MT: What types of cancers are associated with immune suppression in HIV? Lessons from solid organ transplant recipients. Curr Opin HIV AIDS 2009; 4: 35-41.
29. Barbaro G, Barbarini G: HIV infection and cancer in the era of highly active antiretroviral therapy. Oncol Rep 2007; 17: 1121-1126.
30. Durante AJ, Williams AB, Da Costa M, et al: Incidence of anal cytological abnormalities in a cohort of human immunodeficiency virus-infected women. Cancer Epidemiol Biomarkers Prev 2003; 12: 638-642. (Pubitemid 36899844)
31. Daling JR, Sherman KJ, Hislop TG, et al: Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol 1992; 135: 180-189.
32. Frisch M, Glimelius B, Wohlfahrt J, et al: Tobacco smoking as a risk factor in anal cancer: an antiestrogenic mechanism? J Natl Cancer Inst 1999; 91: 708-715. (Pubitemid 29234565)
33. Nieters A, Rohrmann S, Becker N, et al: Smoking and lymphoma risk in the European prospective investigation into cancer and nutrition. Am J Epidemiol 2008; 167: 1081-1089. (Pubitemid 351601238)
34. Bernhard EJ, Brunner TB: Progress towards the use of HIV protease inhibitors in cancer therapy. Cancer Biol Ther 2008; 7: 636-637.
35. Walker DM, Malarkey DE, Seilkop SK, et al: Transplacental cancinogenicity of 3-axido-3-deoxythymidine in B6C3F1 mice and F344 rats. Environ Mol Mutagen 2007; 48: 283-298. (Pubitemid 46536096)
36. Gulick AE, van Leeuwen MT, Falster MO, Vajdic CM: Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a metaanalysis. Lancet 2007; 370: 59-67. (Pubitemid 47017468)
37. New DHHS treatment guidelines green light earlier HIV treatment. Evidence shows benefit of early ART. AIDS Alert 2010; 25: 37-40.